AbbVie Inc, ABBV NYSE 4H

1 de set. de 2022

ABBV
rsi in the oversold territory, which is starting to reverse to the bull side,
flipped bullish on a micro timescale, falling wedge, breaking out to the upside,
first target 140.75, then possible retest before 146.26.
we've been in this long term downtrend channel since April 2022, I expect to break out of it, once
we test 150.36 flip it as support then go for for 175.89 previous April top. fundamentals and news tend
to effect this stock a lot, so with positive momentum and good news. bullish times could be ahead.
Bear scenario is we test 125 before a full reset.

For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.2% over the last 30 days.
The consensus earnings estimate of $13.90 for the current fiscal year indicates a year-over-year change of +9.5%. This estimate has changed +0.2% over the last 30 days.

all this is just my opinion , none of what I say should be taken as financial advice. DYOR
Regards Percy